Disease · EFO_0007585
Cannabis use
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Cannabis use. Diseases, record EFO_0007585. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007585
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Cannabis use
- Open Targets ID
- EFO_0007585
- Other names
- Cannabis consumption, Cannabis use behaviour
- Highest stage of its drugs
- Phase 3, for 1 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE | CHEMBL796 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANNABIDIOL | CHEMBL190461 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RISPERIDONE | CHEMBL85 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DRONABINOL | CHEMBL465 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets43
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | 2 | Cannabinoid CB1 receptor agonist; Cannabinoid CB1 receptor negative allosteric modulator | Phase 2 | https://conductscience.org/library/genes/1268 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 2 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 2 | https://conductscience.org/library/genes/762 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 1 | Dopamine D2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 2 | https://conductscience.org/library/genes/2559 | Drugs and targets |
1 to 10 of 43
See all 43 targetsTrials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01110434 | Biobehavioral Effects of Topiramate on Cannabis-Related Outcomes in Adolescents | Phase 2 | 66 | 2020-09-16 | Cannabis Abuse, Cannabis Dependence | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
| NCT01394185 | Effects of Dronabinol (Oral THC) on Cannabis Use | Phase 1/2 | 25 | 2017-08-03 | Marijuana Smoking | DRONABINOL | Its record names the disease | ClinicalTrials.gov |
| NCT04105231 | Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use | Phase 2 | 64 | Dual Diagnosis | CANNABIDIOL, RISPERIDONE | Its record names the disease | ClinicalTrials.gov | |
| NCT03481959 | Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity | Phase 3 | 3 | Attention Deficit Hyperactivity Disorder (ADHD) | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Topiramate vs Sugar Pill: deaths from any cause | 0 of 40 | 0 of 26 | 66 | NCT01110434 | Trial comparisons |
| Topiramate vs Sugar Pill: serious adverse events | 0 of 40 | 0 of 26 | 66 | NCT01110434 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0007585
GET https://conductscience.org/api/diseases/v1/EFO_0007585/targets?page=2